VERAXA Biotech (VRXA) Building a New Approach to Precision Cancer Therapy

• VERAXA is developing antibody-based cancer therapies aimed at improving the therapeutic window of existing treatment modalities.
• Its proprietary BiTAC platform uses two complementary molecules that are designed to activate cytotoxic activity only when both recognize targets on the same tumor cell.
• The company is applying the BiTAC concept to both antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”), with an emphasis on solid tumors.
• With ADCs and bispecific antibodies attracting substantial investment, VERAXA is operating in oncology markets where technological differentiation can have significant strategic value.

LOS ANGELES, CA - September 16, 2026 (NEWMEDIAWIRE) - VERAXA Biotech (NASDAQ: VRXA) is developing a new generation of antibody-based cancer therapies at a time when oncology research is increasingly focused on a difficult question: how can powerful treatments be made more selective without sacrificing their ability to kill cancer cells? The wiss biotechnology company is approaching that problem through a portfolio of antibody-drug conjugates (“ADCs”), T-cell engagers (“TCEs”) and engineered antibody formats. At the center of the strategy is its proprietary BiTAC, or Bi-targeted Tumor-Associated Cytotoxicity, concept.

The objective is not simply to produce another antibody with a new target. VERAXA is attempting to change the…

Read More

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA

Forward Looking Statements

Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.

View the original release on www.newmediawire.com

This contant was orignally distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is VERAXA Biotech (VRXA) Building a New Approach to Precision Cancer Therapy.